by Lynda Charters – Opthamology –
A newly published study found that intravitreal injection of autologous CD34+ stem cells is well tolerated and feasible for treating loss of vision resulting from central retinal vein occlusion (CRVO), according to a press release issued by the Emmes Company working in collaboration with the UC Davis Eye Center, Sacramento, CA.
The results show that the injection of the stem cells was deemed well tolerated and feasible, establishing an important safety foundation for future studies, according to Susanna S. Park, MD, PhD, and colleagues. She is from the Department of Ophthalmology & Vision Science, University of California Davis Health, Sacramento.
